Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
Shuchi Gulati(Comprehensive Blood & Cancer Center), Yu Shyr(Vanderbilt University), Erika Ruíz‐García(Instituto Nacional de Cancerología), Deborah B. Doroshow(Icahn School of Medicine at Mount Sinai), Rebecca L. Zon(Brigham and Women's Hospital), Daniel Flora(St. Elizabeth Healthcare), Pankil Shah(Mays Cancer Center at UT Health San Antonio), James J. Yoon(University of Michigan), Natalie Knox Heater(Loyola University Medical Center), Tahir Latif(University of Cincinnati), Taylor K. Nonato(University of California San Diego), Petros Grivas(Seattle Cancer Care Alliance), Monika Joshi(Pennsylvania State University), Pedram Razavi(Memorial Sloan Kettering Cancer Center), Joshua Fein(Dana-Farber Cancer Institute), Vadim S. Koshkin(UCSF Helen Diller Family Comprehensive Cancer Center), Chinmay Jani(Mount Auburn Hospital), Joy Awosika(University of Cincinnati), Chih–Yuan Hsu(Vanderbilt University Medical Center), Lisa B. Weissmann(Mount Auburn Hospital), Diana Vilar‐Compte(Instituto Nacional de Cancerología), Clara Hwang(Henry Ford Health System), Daniel De‐la‐Rosa‐Martinez(Instituto Nacional de Cancerología), Elizabeth J. Klein(Brown University), Renée Maria Saliby(Yale University), Alicia Beeghly(Vanderbilt University), Rana R. McKay(University of California San Diego), Sanjay Mishra(Vanderbilt University Medical Center), Elizabeth A. Griffiths(Roswell Park Comprehensive Cancer Center), Trisha M. Wise‐Draper(University of Cincinnati), Susan Alsamarai(Hartford Hospital), Christopher R. Friese(University of Michigan), Babar Bashir(Thomas Jefferson University), Stephanie Berg(Loyola University Medical Center), Hyma Polimera(Penn State Milton S. Hershey Medical Center), Ziad El-Bakouny(Dana-Farber Cancer Institute), Michael Wotman(The University of Texas MD Anderson Cancer Center), Matthew Puc(Virtua Health), Cy R. Wilkins(Memorial Sloan Kettering Cancer Center), Daniel H. Kwon(Harvard University), Vicky Tagalakis(Jewish General Hospital), Ariel Fromowitz(Albert Einstein College of Medicine), Sunny Singh(Henry Ford Hospital), Elizabeth S. Nakasone(Cold Spring Harbor Laboratory), Pamela Egan(Brown University), Aditi Shastri(Albert Einstein College of Medicine), Surbhi Shah(WinnMed), Gayathri Nagaraj(Loma Linda University), Hina Khan, Chris Labaki(Beth Israel Deaconess Medical Center)
Cited by 10
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k